142 related articles for article (PubMed ID: 22409255)
1. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites.
Tognolini M; Giorgio C; Hassan Mohamed I; Barocelli E; Calani L; Reynaud E; Dangles O; Borges G; Crozier A; Brighenti F; Del Rio D
J Agric Food Chem; 2012 Sep; 60(36):8877-84. PubMed ID: 22409255
[TBL] [Abstract][Full Text] [Related]
2. Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system.
Mohamed IH; Giorgio C; Bruni R; Flammini L; Barocelli E; Rossi D; Domenichini G; Poli F; Tognolini M
Pharmacol Res; 2011 Nov; 64(5):464-70. PubMed ID: 21742039
[TBL] [Abstract][Full Text] [Related]
3. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
Wykosky J; Gibo DM; Stanton C; Debinski W
Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
[TBL] [Abstract][Full Text] [Related]
4. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
5. The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells.
Giorgio C; Mena P; Del Rio D; Brighenti F; Barocelli E; Hassan-Mohamed I; Callegari D; Lodola A; Tognolini M
Mol Nutr Food Res; 2015 Nov; 59(11):2155-67. PubMed ID: 26307544
[TBL] [Abstract][Full Text] [Related]
6. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
7. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
8. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
[TBL] [Abstract][Full Text] [Related]
9. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
10. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
11. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
12. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).
Nasreen N; Mohammed KA; Lai Y; Antony VB
Cancer Lett; 2007 Dec; 258(2):215-22. PubMed ID: 17949899
[TBL] [Abstract][Full Text] [Related]
13. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.
Lin KT; Gong J; Li CF; Jang TH; Chen WL; Chen HJ; Wang LH
Cancer Res; 2012 Jun; 72(12):3000-9. PubMed ID: 22659453
[TBL] [Abstract][Full Text] [Related]
14. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
15. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
[TBL] [Abstract][Full Text] [Related]
16. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas).
Carter N; Nakamoto T; Hirai H; Hunter T
Nat Cell Biol; 2002 Aug; 4(8):565-73. PubMed ID: 12134157
[TBL] [Abstract][Full Text] [Related]
17. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells.
Zhou N; Zhao WD; Liu DX; Liang Y; Fang WG; Li B; Chen YH
Microvasc Res; 2011 Sep; 82(2):113-21. PubMed ID: 21726568
[TBL] [Abstract][Full Text] [Related]
20. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]